An Assessment of Market Opportunities for ReFilx: A Novel Soft Tissue Filler

肿块切除或保乳手术(BCS)是大多数乳腺癌(BC)治疗的重要组成部分，但由于手术造成的巨大软组织缺陷，它往往会导致不良的美容效果。人们对更好的美容效果的需求越来越大，因为这些患者现在预计可以长期存活，而糟糕的美容往往会不断提醒他们的疾病，这反过来可能会影响他们的生活质量。ReFilx是这项赠款提案中讨论的发明，它代表了一种简单、成本效益高、用途广泛、永久性和美观的软组织缺陷矫正解决方案，有可能减少手术时间/外科解剖、并发症发生率和阳性切缘的发生率。ReFilx是新型氨基酸衍生的可生物降解聚氨酯(PU)多孔泡沫塑料的一个子组，用于BCS或BC相关活检后的乳房体积修复软组织填充物。我们的活体猪研究表明，ReFilx满足以下植入标准：保持乳房的形状/体积和自然硬度，支持细胞/组织渗透、新生血管和宿主组织整合，同时促进伤口修复和低炎症。拟议市场评估的主要目的是通过评估市场规模、竞争格局、进入壁垒和市场趋势来评估拟议产品的市场潜力。还将进行分析，以评估影响技术商业化的潜在因素，包括最终用户采用产品、产品定位、潜在分销渠道、监管因素以及通过保险报销等问题。

Lumpectomy or breast conserving surgery (BCS) is an essential component of most breast cancer (BC) treatments but it can often result in poor cosmetic outcomes due to large soft tissue defects from the procedure. There is an increasing demand for better cosmetic outcomes as these patients are now expected to survive long-term, and poor cosmesis can often serve as a constant reminder of their illness, which in turn may impact their quality of life. ReFilx, which is the invention discussed in this grant proposal, represents a simple, cost-effective, versatile, permanent and aesthetically superior solution for soft tissue defect correction with the potential of reducing surgery time/surgical dissection, complication rates and the incidence of positive margins. ReFilx is a sub-group of novel amino acid-derived biodegradable polyurethane (PU) porous foams that are intended for use as soft tissue fillers for breast volume restoration following BCS or biopsies associated with BC. Our in vivo porcine studies have shown that ReFilx satisfies the implant criteria of preserving breast shape/volume and natural stiffness, supporting cell/tissue infiltration, neovascularization and host tissue integration as well as promoting wound repair and low inflammation simultaneously. The main aim of the proposed market assessment is to assess the market potential of the proposed product through assessment of market size, competitive landscape, barriers to entry, and market trends. Analysis will also be performed to assess potential factors affecting the commercialization of the technology, including issues regarding product adoption by end-users, product positioning, potential distribution channels, regulatory factors, and reimbursement through insurance.